The global Respiratory Syncytial Virus (RSV) therapeutics market is experiencing significant growth, driven by the increasing prevalence of RSV infections and advancements in treatment options. In 2023, the market was valued at approximately USD 1.5 billion and is projected to reach USD 5.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 15% during the forecast p... https://www.analystviewmarketinsights.com/reports/report-highlight-respiratory-syncytial-virus-therapeutics-market